Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

AbbVie has secured its fourth FDA approval for Vraylar, adding adjunctive therapy of major depressive disorder (MDD) to a list that includes schizophrenia and manic and depressive episodes in ...

As a measles outbreak causes dozens of illnesses in West Texas, it’s important to know how to identify signs of the illness – ...

A personalized circadian Zeitgeber therapy as an adjunctive treatment for alcohol use disorder patients: results of a pilot ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Concomitant use of statins improved survival among people with cancer treated with immune checkpoint inhibitors, according to ...

On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 /TuHURA Biosciences, Inc.

Alto Neuroscienc announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining ...

Table 1. Clinical and preclinical studies reporting the effect of the KD on SUD. KD may be effective as a potential adjunctive therapy for SUD treatment. Importantly, it may have targeted protective ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...